Up a level |
Jump to: 2017
Number of items: 1.
2017
Stenzl, A., Feyerabend, S., Syndikus, I., Sarosiek, T., Kuebler, H., Heidenreich, A., Cathomas, R., Gruellich, C., Loriot, Y., Perez Gracia, S. L., Gillessen, S., Klinkhardt, U., Schroeder, A., Schoenborn-Kellenberger, O., Reus, V., Koch, S. D., Hong, H. S., Seibel, T., Fizazi, K. and Gnad-Vogt, U. (2017). Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041